TY - JOUR
T1 - Outcome predictors of radical cystectomy in patients with cT4 prostate cancer
T2 - a multi-institutional study of 62 patients
AU - the European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPAcT)
AU - Spahn, Martin
AU - Morlacco, Alessandro
AU - Boxler, Silvan
AU - Joniau, Steven
AU - Briganti, Alberto
AU - Montorsi, Francesco
AU - Gontero, Paolo
AU - Bader, Pia
AU - Frohneberg, Detlef
AU - van Poppel, Hein
AU - Karnes, Robert Jeffrey
N1 - Publisher Copyright:
© 2017 The Authors BJU International © 2017 BJU International Published by John Wiley & Sons Ltd
PY - 2017/11
Y1 - 2017/11
N2 - Objectives: To identify which patients with macroscopic bladder-infiltrating T4 prostate cancer (PCa) might have favourable outcomes when treated with radical cystectomy (RC). Materials and Methods: We evaluated 62 patients with cT4cN0–1 cM0 PCa treated with RC and pelvic lymph node dissection between 1972 and 2011. In addition to descriptive statistics, the Kaplan–Meier method and log-rank tests were used to depict survival rates. Univariate and multivariate Cox regression analysis tested the association between predictors and progression-free, PCa-specific and overall survival. Results: Of the 62 patients, 19 (30.6%) did not have clinical progression during follow-up, two (3.2%) had local recurrence, and 32 (51.6%) had haematogenous and nine (14.5%) combined pelvic and distant metastasis. Forty patients (64.5%) died, 34 (54.8%) from PCa and six (9.7%) from other causes. The median (range) survival time of the 19 patients who were metastasis-free at last follow-up was 86 (1–314) months, 8/19 patients had a follow-up of >5 years, and five patients survived metastasis-free for >15 years. Patients without seminal vesicle invasion (SVI) had the best outcomes, with an estimated 10-year PCa-specific survival of 75% compared with 24% for patients with SVI. Conclusion: For cT4 PCa RC can be an appropriate treatment for local control and part of a multimodality-treatment approach. Although recurrences are probable, these do not necessarily translate into cancer-specific death. Men without SVI had a 75% 10-year PCa-specific survival. Although outcomes for patients with SVI are not as favourable, there can be good local control; however, these patients are at higher risk of progression and may need more aggressive systemic treatment.
AB - Objectives: To identify which patients with macroscopic bladder-infiltrating T4 prostate cancer (PCa) might have favourable outcomes when treated with radical cystectomy (RC). Materials and Methods: We evaluated 62 patients with cT4cN0–1 cM0 PCa treated with RC and pelvic lymph node dissection between 1972 and 2011. In addition to descriptive statistics, the Kaplan–Meier method and log-rank tests were used to depict survival rates. Univariate and multivariate Cox regression analysis tested the association between predictors and progression-free, PCa-specific and overall survival. Results: Of the 62 patients, 19 (30.6%) did not have clinical progression during follow-up, two (3.2%) had local recurrence, and 32 (51.6%) had haematogenous and nine (14.5%) combined pelvic and distant metastasis. Forty patients (64.5%) died, 34 (54.8%) from PCa and six (9.7%) from other causes. The median (range) survival time of the 19 patients who were metastasis-free at last follow-up was 86 (1–314) months, 8/19 patients had a follow-up of >5 years, and five patients survived metastasis-free for >15 years. Patients without seminal vesicle invasion (SVI) had the best outcomes, with an estimated 10-year PCa-specific survival of 75% compared with 24% for patients with SVI. Conclusion: For cT4 PCa RC can be an appropriate treatment for local control and part of a multimodality-treatment approach. Although recurrences are probable, these do not necessarily translate into cancer-specific death. Men without SVI had a 75% 10-year PCa-specific survival. Although outcomes for patients with SVI are not as favourable, there can be good local control; however, these patients are at higher risk of progression and may need more aggressive systemic treatment.
KW - #PCSM
KW - #ProstateCancer
KW - #uroonc
KW - cystectomy
KW - high-risk prostate cancer
KW - locally advanced prostate cancer
KW - multimodality treatment
KW - surgery
KW - surgery
UR - http://www.scopus.com/inward/record.url?scp=85017169994&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017169994&partnerID=8YFLogxK
U2 - 10.1111/bju.13818
DO - 10.1111/bju.13818
M3 - Article
C2 - 28220605
AN - SCOPUS:85017169994
SN - 1464-4096
VL - 120
SP - E52-E58
JO - BJU international
JF - BJU international
IS - 5
ER -